Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Febrile Neutropenia

Febrile Neutropenia

Part of Neutropenia

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Febrile Neutropenia

6 trials tracked for Febrile Neutropenia: 1 in phase 3 or 4.

6Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Other / NA 5
  1. Phase 4 Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients Completed
  2. N/A Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor Completed
  3. N/A Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy Completed
  4. N/A S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) Completed
  5. N/A Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia Completed
  6. N/A Observational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical Options Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review and meta-analysis compares piperacillin-tazobactam and cefepime in pediatric febrile neutropenia
Pediatrics Meta-analysis
Systematic review and meta-analysis compares piperacillin-tazobactam and cefepime in pediatric febrile neutropenia Two Antibiotics for Fever in Kids: One Works a Day Faster
This systematic review and meta-analysis evaluates piperacillin-tazobactam versus cefepime monotherapy in 470 episodes of pediatric febrile …
When a child on chemotherapy gets a fever, doctors have two main antibiotic choices, and a new analysis of 470 cases shows they work equally…
May 7, 2026
FDA Approves Cefepime for Injection and Dextrose Injection (cefepime) for Moderate to Severe Pneumonia and Other Infections
Infectious Disease FDA Approval
FDA Approves Cefepime for Injection and Dextrose Injection (cefepime) for Moderate to Severe Pneumonia and Other Infections The FDA approved a new ready-to-use version of an antibiotic called cefepime for serious infections
The FDA approved cefepime in a dextrose injection formulation for intravenous treatment of moderate to severe pneumonia, febrile neutropenia…
The FDA approved a ready-to-use antibiotic for serious infections like pneumonia and urinary tract infections in hospitalized patients.
FDA Apr 10, 2026

Research across Neutropenia

Related studies from across the Neutropenia family.

Meta-analysis finds fluoroquinolone prophylaxis reduces febrile neutropenia in pediatric ALL
Oncology Meta-analysis
Meta-analysis finds fluoroquinolone prophylaxis reduces febrile neutropenia in pediatric ALL Fluoroquinolone antibiotics lower febrile neutropenia risk in children with acute lymphoblastic leukemia during treatment start
This systematic review and meta-analysis of 991 children with acute lymphoblastic leukemia found that fluoroquinolone prophylaxis reduced fe…
A review of children with acute lymphoblastic leukemia shows fluoroquinolone antibiotics reduce febrile neutropenia risk. This finding sugge…
May 1, 2026
Risk factors for multidrug-resistant organism infections in neutropenic patients
Infectious Disease Cohort
Risk factors for multidrug-resistant organism infections in neutropenic patients Doctors Can Now Predict Deadly Infections in Chemo Patients Before They Strike
This observational cohort study in 391 neutropenic patients identified risk factors for multidrug-resistant organism infections.
This new prediction model could help doctors protect vulnerable patients from life-threatening infections that resist standard treatment.
Frontiers Apr 23, 2026
Subcutaneous PEG-rhG-CSF reduced grade ≥3 neutropenia and CIN in GI cancer patients receiving oral chemotherapy
Oncology RCT
Subcutaneous PEG-rhG-CSF reduced grade ≥3 neutropenia and CIN in GI cancer patients receiving oral chemotherapy New Shot Cuts Severe Low White Blood Cell Risk
This prospective, single-center, open-label, exploratory, non-randomized controlled study evaluated subcutaneous PEG-rhG-CSF in 43 gastroint…
A simple shot given before chemotherapy could keep your body's infection-fighting cells strong when taking oral cancer pills.
Frontiers Apr 16, 2026